Shots:

• The US FDA has approved Jesduvroq, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor as 1st oral treatment of anaemia due to CKD undergoing dialysis
• The approval was based on the P-III (ASCEND-D) trial results evaluating Jesduvroq vs recombinant human erythropoietin in 2964 dialysis patients who were switched to receive daprodustat ESA control from an SoC ESA therapy
• The results showed that daprodustat was non-inferior to ESAs regarding the change in the Hb level from baseline & CV outcomes, the major adverse cardiovascular event (25.2% vs 26.7%) during a median follow-up of 2.5yrs., patients with other AEs were similar in 2 groups, mean change in Hb level from baseline to 28-52wks. The MAA for daprodustat is under EMA’s review with a regulatory decision expected in H1’23

Ref: GSK | Image: GSK

Related News:- WuXi Signed a License Agreement with GSK to Develop Multiple Novel Bi- & Multi-specific T Cell Engagers to Treat Cancer